The latest updates from AFAR.

Grantee in the News: Randall Bateman on latest DIAN-TU trial in Reuters' BioWorld Today

Jan 19

Grantee in the News: Randall Bateman on latest DIAN-TU trial in Reuters' BioWorld Today View MoreBACK

Reuters’ BioWorld Today recently highlighted insights of two-time AFAR grantee and 2015 recipient of the AFAR-administered MetLife Foundation Award for Medical Research in Alzheimer’s Disease, Randall Bateman, MD.

Under Bateman’s leadership, a research team at Washington University School of Medicine in St. Louis  has selected a third investigational drug to be tested in the worldwide DIAN-TU trial.

As BioWorld notes:

The Dominantly Inherited Alzheimer's Network Trial Unit (DIAN-TU) study, involves people with an inherited predisposition to develop AD at a young age, usually in their 30s, 40s or 50s. Participants already enrolled will continue on their existing drug regimens, and more volunteers with no or mild symptoms of cognitive impairment will be enrolled to evaluate the third drug.

This new, third compound is provided by Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, is providing the third compound, which joins gantenerumab, from Basel, Switzerland-based Roche AG, and solanezumab, from Eli Lilly and Co., of Indianapolis

On the initial findings, Bateman shares:

One lesson learned only recently is that "it appears amyloid-beta [a-beta] begins to deposit in the brain about 15 years before peoples' symptoms first begin," he said, whereas tau tangles, the second pathology in AD, don't crop up until right around the time symptoms make themselves known. "There's a temporal relationship that we didn't appreciate before."

Read the full article here.

Randall Bateman, MD, is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine.

For more information on Alzheimer’s disease, download our InfoAging guide here.